Screener Summaries Updates Institutions Sign In More Updates › Financing › GOSS Financing · Jul 1, 2026
Gossamer Bio, Inc. announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due… GOSS Gossamer Bio, Inc.
Gossamer Bio, Inc. announced the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030. The conversion rate is set at 5,347.5936 shares of common stock per $1,000 principal amount, resulting in a conversion price of approximately $0.19 per share. Additionally, the initial exercise price for its purchase warrants to buy common stock is $0.34 per share. Gossamer Bio, Inc. is a biopharmaceutical company.
More from Gossamer Bio, Inc. Stockholders approve issuance of shares exceeding 20% ownership threshold under Nasdaq rules Oct 28, 2026 Gossamer Bio, Inc. received a letter from Nasdaq confirming it has regained compliance with the minimum bid price… Sep 28, 2026 Gossamer Bio appointed Gregory A. Ciongoli as a Class III director effective September 16, 2026, with his term… Sep 16, 2026 Gossamer Bio, Inc. filed a Certificate of Amendment to its Charter on September 10, 2026, effecting a 1-for-80 reverse… Sep 11, 2026 Gossamer Bio announced that its board selected a 1-for-80 reverse stock split ratio for its common stock Sep 9, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
